Handelsbanken Fonder AB continued to hold its stake in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent filing with the SEC. The firm owned 23,140 shares of the medical research company’s stock at the end of the second quarter. Handelsbanken Fonder AB’s holdings in Amgen were worth $3,985,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its holdings in Amgen by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after acquiring an additional 195,200 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in Amgen by 1.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock valued at $474,947,000 after acquiring an additional 45,403 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in Amgen by 3.1% during the 1st quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock valued at $446,250,000 after acquiring an additional 81,362 shares during the period. Swiss National Bank boosted its holdings in Amgen by 26.5% during the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after acquiring an additional 551,600 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in Amgen by 0.7% during the 1st quarter. Ameriprise Financial Inc. now owns 1,479,687 shares of the medical research company’s stock valued at $242,555,000 after acquiring an additional 10,109 shares during the period. Institutional investors own 78.14% of the company’s stock.

Amgen Inc. (NASDAQ:AMGN) traded down 1.04% on Friday, reaching $187.47. The company’s stock had a trading volume of 5,348,992 shares. The firm’s 50 day moving average price is $175.31 and its 200-day moving average price is $169.32. The company has a market capitalization of $136.79 billion, a price-to-earnings ratio of 17.08 and a beta of 1.35. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $191.10.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. During the same quarter last year, the business posted $2.84 EPS. Amgen’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities analysts predict that Amgen Inc. will post $12.57 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.45%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s payout ratio is 41.93%.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/17/amgen-inc-amgn-position-held-by-handelsbanken-fonder-ab.html.

Several brokerages have recently issued reports on AMGN. UBS AG reiterated a “neutral” rating and issued a $175.00 price objective (up previously from $174.00) on shares of Amgen in a research note on Tuesday, June 13th. Morgan Stanley lifted their price objective on Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, June 13th. BMO Capital Markets reiterated a “buy” rating and issued a $198.00 price objective (down previously from $200.00) on shares of Amgen in a research note on Monday, May 22nd. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $203.00 price objective (up previously from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. Finally, Royal Bank Of Canada began coverage on Amgen in a research note on Thursday. They issued a “sector perform” rating and a $192.00 price objective for the company. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. Amgen presently has an average rating of “Buy” and a consensus price target of $186.14.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.